Asselah J, Sperlich C. Post-docetaxel options for further survival benefit in metastatic castration-resistant prostate cancer: Questions of choice. CUAJ [Internet]. 2013 Feb. 19 [cited 2024 May 12];7(1-2-S1):S11-S17. Available from: https://cuaj.ca/index.php/journal/article/view/274